OXIDATION;
CLINICAL DISCRIMINATION;
PRIMARY HYPERPARATHYROIDISM;
HYPERCALCEMIA OF MALIGNANCY;
D O I:
10.1177/000456329102800207
中图分类号:
R446 [实验室诊断];
R-33 [实验医学、医学实验];
学科分类号:
1001 ;
摘要:
We report the development of a two-site immunoradiometric assay for PTH(1-84) based on two site-specific monoclonal antibodies-3B3 (radiolabelled antibody) specific for PTH(1-34) and ESQ1 (on solid phase) specific for PTH(74-84). Antibody 3B3 is sensitive to the oxidation of the methionine residues in PTH(1-34) therefore hydrogen peroxide (0.1 M) is added to the incubation mixture. Validation studies confirm quantitative recovery of both oxidized and reduced PTH(1-84). The assay has a minimum detection limit of 0.5 pmol/L and a range of 1.5-250 pmol/L with an intra-assay CV of less than 10% (2.8-250 pmol/L less than 5% CV). Studies on clinical samples indicate good discrimination between normal subjects (mean 2.21; range 1.0-5.0 pmol/L) and patients with primary hyperparathyroidism (mean 21.0; range 5.8-100 pmol/L) who in turn are well separated from patients with hypercalcaemia of malignancy (14/18 < 0.5 pmol/L).